IL29 Protein (AA 23-200)

N° du produit ABIN2667435

Protéine Recombinant IL29 exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour IL29 Protein (AA 23-200) (ABIN2667435)

Antigène: IL29 (Interleukin 29 (IL29))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Chemical

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Pureté: >98 % , as determined by Coomassie stained SDS-PAGE.

Détail du produit

Attributs du protein: AA 23-200

niveau d'endotoxine:

Less than 0.1 ng per μg of protein.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: ED50 = 0.2 - 0.5 ng/ml, corresponding to a specific activity of 2.0 x 106 - 5.0 x 106 units/mg, as measured by its ability to activate STAT phosphorylation in an ISRE Luciferase Reporter Assay using human colon carcinoma COLO205 cells.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized, carrier-free.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored at -20°C or -70°C.

Détail du antigène

Antigène: IL29 (Interleukin 29 (IL29))

Autre désignation: IFN-1

Sujet: IFN-λ1, also known as IL-29, is a member of the type III interferon (IFN) family. Type III interferons, including IFN-λ1, IFN-λ2 and IFN-λ3, are produced upon virus infection and are functionally similar to type I interferon (IFN-α/β). IFN-λ binds to a heterodimeric receptor composed of the IFN-λ receptor 1 (IFNLR1) and the interleukin-10 receptor 2 (IL-10R2), subsequently tranducing signal through the JAK-STAT pathway and leading to transactivation of various IFN-stimulated genes (ISGs). IFN-λ has been demonstrated to mediate an antiviral immune response against several viruses, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). In contrast to type I or type II interferons, IFN-λ receptor is expressed preferentially on epithelial-like cells and some immune cells. Because the response to IFN-λ is highly restricted to certain cell types, IFN-λ is considered a potential therapuetic agent for the treatment of viral diseases with less side effects when compared with type I interferon.

Poids moléculaire: The 178 amino acid recombinant protein has a predicted molecular mass of approximately 19.8 kDa. The predicted N-terminal amino acid is Pro.